September 30, 2024 10:51 AM EDT
News Briefing

CSPC, Al­pham­ab On­col­o­gy make an ADC deal; Visen’s IPO in Hong Kong

Kyle LaHucik

Senior Reporter

Plus, news about Se­quen­tia Biotech:

CSPC, Al­pham­ab On­col­o­gy ink ADC deal: CSPC Phar­ma­ceu­ti­cal’s JMT-Bio Tech­nol­o­gy said it will pay RMB 400 …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

A service from the Financial Times